At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 16 enrolled
Drug / intervention
Eribulindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
ERibulin in Advanced Solitary Fibrous Tumor, an ItaliaN Sarcoma Group Phase II Study (ERASING)
In Brief
A Phase 2 clinical trial evaluating Eribulin for Solitary Fibrous Tumor. Completed, enrolled 16 participants across 3 sites.
Detailed Summary
Phase II study on advanced Solitary Fibrous Tumor (SFT) treated with eribulin
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolitary Fibrous Tumor
CountriesItaly
CollaboratorsEisai Inc.
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedFeb 2019
Enrollment StartJul 2019
Primary CompletionSep 2024
TodayJul 2026
First PostedFeb 15, 2019
Enrollment StartJul 17, 2019
Primary CompletionSep 18, 2024
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 7.4 years ago
Interventions
Eribulindrug
Treatment with eribulin